Case number 2017-2149
HZNP Finance Limited v. Actavis Laboratories UT, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | HZNP MEDICINES LLC v. ACTAVIS LABORATORIES UT, INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| Apr 23, 2021 | 0 | HZNP FINANCE LIMITED v. ACTAVIS LABORATORIES UT, INC. [ORDER DENYING REHEARING EN BANC] [precedential] (0) |
| Nov 3, 2020 | 99 | The petition for writ of certiorari, No. 20-88, filed on 07/24/2020, was Denied on 11/02/2020. [733336] [JAB] [Entered: 11/03/2020 02:05 PM] (1) |
| Jul 30, 2020 | 98 | Petition for writ of Certiorari filed on 07/24/2020, and placed on the docket 07/29/2020, in the Supreme Court of the United States. Supreme Court #: 20-88, HZNP Finance Limited, et al. v. Actavis Laboratories UT, Inc. [711369] [JAB] [Entered: 07/30/2020 03:37 PM] (1) |
| Mar 3, 2020 | 97 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [675872] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 03/03/2020 01:50 PM] (1) |
| Feb 25, 2020 | 96 | PRECEDENTIAL ORDER filed denying petition for en banc rehearing [88] filed by HZNP Finance Limited and Horizon Therapeutics USA, Inc. Lourie, Circuit Judge, with whom Newman, O'Malley, and Stoll, Circuit Judges, join, dissents from the denial of the petition for rehearing en banc. By: Per Curiam. Service as of this date by the Clerk of Court. [673877] [MJL] [Entered: 02/25/2020 09:17 AM] (7) |
| Dec 23, 2019 | 95 | 18 paper copies of the response [94] received from Cross-Appellant Actavis Laboratories UT, Inc. [658726] [JAB] [Entered: 12/26/2019 08:12 AM] (0) |
| Dec 20, 2019 | 93 | Amended Certificate of Interest for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 12/20/2019 by email. [658358] [17-2149] [Michael Joffre] [Entered: 12/20/2019 06:39 PM] (3) |
| Dec 20, 2019 | 94 | RESPONSE of Cross-Appellant Actavis Laboratories UT, Inc. to the petition for en banc rehearing [88] filed by Appellants Horizon Therapeutics USA, Inc. and HZNP Finance Limited. Service: 12/20/2019 by email. [658360] [17-2149] [Michael Joffre] [Entered: 12/20/2019 06:43 PM] (24) |
| Dec 6, 2019 | 92 | The court invites a response from Cross-Appellant Actavis Laboratories UT, Inc. to the petition for en banc rehearing filed by Appellants in 17-2149. The response is due on or before 12/20/2019. [654653] [JAB] [Entered: 12/06/2019 02:27 PM] (1) |
| Nov 20, 2019 | 91 | 18 paper copies of the petition for en banc rehearing [88] received from Appellants HZNP Finance Limited and Horizon Therapeutics USA, Inc. [650817] [JAB] [Entered: 11/20/2019 11:19 AM] (0) |
| Nov 19, 2019 | 89 | Notice of Correction to Doc No. [87] for Appellants HZNP Finance Limited and Horizon Therapeutics USA, Inc.. Service: 11/19/2019 by email. [650494] [17-2149] [Caryn Borg-Breen] [Entered: 11/19/2019 11:35 AM] (3) |
| Nov 19, 2019 | 90 | The party filed a corrected petition and is withdrawing [87] petition for en banc rehearing filed by Appellants HZNP Finance Limited and Horizon Therapeutics USA, Inc. The previously filed petition is withdrawn. [650495] [JAB] [Entered: 11/19/2019 11:48 AM] (0) |
| Nov 18, 2019 | 87 | Petition for en banc rehearing filed by Appellants HZNP Finance Limited and Horizon Therapeutics USA, Inc. Service: 11/18/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 11/20/2019 [650311] [17-2149] This petition has been replaced. See Doc. No. [90]. [Caryn Borg-Breen] [Entered: 11/18/2019 04:31 PM] (0) |
| Nov 18, 2019 | 88 | Petition for en banc rehearing filed by Appellants Horizon Therapeutics USA, Inc. and HZNP Finance Limited. Service: 11/18/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 11/20/2019 [650321] [17-2149] [Caryn Borg-Breen] [Entered: 11/18/2019 04:52 PM] (82) |
| Nov 14, 2019 | 86 | ORDER filed granting motion to modify the official caption [83] filed by Appellants Horizon Pharma USA, Inc. and HZNP Medicines LLC. The revised official caption is reflected in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [649277] [JAB] [Entered: 11/14/2019 12:27 PM] (2) |
| Nov 13, 2019 | 85 | 18 paper copies of the petition for en banc rehearing [84] received from Appellants HZNP Medicines LLC and Horizon Pharma USA, Inc. [648968] [JAB] [Entered: 11/13/2019 12:20 PM] (0) |
| Nov 11, 2019 | 83 | MOTION of Appellants Horizon Pharma USA, Inc. and HZNP Medicines LLC to modify the official caption [Consent: unopposed]. Service: 11/11/2019 by email. [648412] [17-2149] [Caryn Borg-Breen] [Entered: 11/11/2019 01:14 PM] (8) |
| Nov 11, 2019 | 84 | Petition for en banc rehearing filed by Appellants Horizon Pharma USA, Inc. and HZNP Medicines LLC. Service: 11/11/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 11/13/2019 [648419] [17-2149] [Caryn Borg-Breen] [Entered: 11/11/2019 03:22 PM] (82) |
| Oct 10, 2019 | 81 | OPINION filed for the court by Prost, Chief Judge; Newman, Circuit Judge and Reyna, Circuit Judge. Opinion concurring in part and dissenting in part filed by Circuit Judge Newman. Precedential Opinion. [641453] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:50 AM] (55) |
| Oct 10, 2019 | 82 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [641454] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:51 AM] (2) |
| Jan 11, 2019 | 80 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [79], ERROR: The entry of appearance for Jessica T. Mackay does not match the information in the attoreny's user account (Jessica Tyrus). CORRECTION: Please update as needed to ensure the information with the PACER Service Center matches the entry of appearance. [577500] [JAB] [Entered: 01/11/2019 08:35 AM] (0) |
| Jan 10, 2019 | 78 | Amended Entry of appearance for Jessica T. Mackay as of counsel for Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited, HZNP Limited and HZNP Medicines LLC. Service: 01/10/2019 by email. [577278] [17-2149] [Jessica Mackay] [Entered: 01/10/2019 11:51 AM] (2) |
| Jan 10, 2019 | 79 | Corrected Entry of appearance for Jessica T. Mackay as of counsel for Appellants HZNP Medicines LLC and Horizon Pharma USA, Inc.. Service: 01/10/2019 by email. [577293] [17-2149] [Jessica Mackay] [Entered: 01/10/2019 12:26 PM] (2) |
| Oct 5, 2018 | 75 | Letter from Appellant HZNP Medicines LLC in response to citation to supplemental authority filed October 2, 2018. Service: 10/05/2018 by email. [555264] [17-2149] [Caryn Borg-Breen] [Entered: 10/05/2018 01:37 PM] (3) |
| Oct 5, 2018 | 76 | NOTICE OF NON-COMPLIANCE: The submission of Appellant HZNP Medicines LLC, Letter in response to citation to supplemental authority [75], is not in compliance with the rules of this court (see attached). Compliant document due on 10/15/2018. Service as of this date by the Clerk of Court.[555276] [JAB] [Entered: 10/05/2018 01:53 PM] (2) |
| Oct 5, 2018 | 77 | RESPONSE of Appellants HZNP Medicines LLC and Horizon Pharma USA, Inc. to the supplemental authority [74] filed by Cross-Appellant Actavis Laboratories UT, Inc.. Service: 10/05/2018 by email. [555338] [17-2149] [Caryn Borg-Breen] [Entered: 10/05/2018 03:58 PM] (3) |
| Oct 2, 2018 | 74 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 10/02/2018 by email. [554224] [17-2149] [Michael Joffre] [Entered: 10/02/2018 03:21 PM] (33) |
| Sep 25, 2018 | 73 | ORDER filed granting motion to substitute party [72]. HZNP Limited and Horizon Pharma Ireland Limited are substituted by HZNP Medicines LLC. The revised official caption is reflected in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [552261] [JAB] [Entered: 09/25/2018 08:57 AM] (2) |
| Sep 20, 2018 | 72 | MOTION of HZNP Medicines LLC to substitute party [Consent: unopposed]. Service: 09/20/2018 by email. [551353] [17-2149] [Caryn Borg-Breen] [Entered: 09/20/2018 12:31 PM] (10) |
| Jun 5, 2018 | 71 | Submitted after ORAL ARGUMENT by Caryn Borg-Breen for Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited and Michael E. Joffre for Actavis Laboratories UT, Inc. Panel: Judge: Prost , Judge: Newman , Judge: Reyna. [526861] [JAB] [Entered: 06/05/2018 10:14 AM] (0) |
| May 15, 2018 | 70 | Response to oral argument order from the Cross-Appellant Actavis Laboratories UT, Inc.. Designating Michael E. Joffre to argue.. Designating 12 minutes for argument. Reserving 3 minutes for rebuttal. [17-2149] [Michael Joffre] [Entered: 05/15/2018 11:25 AM] (0) |
| May 14, 2018 | 69 | Clerk's Note to the File: The courtroom for the June 5, 2018 oral argument has changed. Argument for this case will now be heard in Courtroom 201. (Ref: calendar notice , [67]) [521361] [JAB] [Entered: 05/14/2018 12:00 PM] (0) |
| May 11, 2018 | 68 | Response to oral argument order from the Appellants Horizon Pharma Ireland Limited, Horizon Pharma USA, Inc. and HZNP Limited. Designating Caryn C. Borg-Breen to argue.. Designating 10 minutes for argument. Reserving 5 minutes for rebuttal. [17-2149] [Caryn Borg-Breen] [Entered: 05/11/2018 03:02 PM] (0) |
| Apr 20, 2018 | 67 | NOTICE OF CALENDARING. Panel: 1806F. Case scheduled Jun 05, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to oral argument order due: 05/15/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [515668] [JAB] [Entered: 04/20/2018 01:48 PM] (0) |
| Feb 22, 2018 | 65 | Notice from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. regarding conflicts with oral argument (Counsel for Plaintiffs-Appellants has conflicts during April 30-May 4, 2018 due to trial in another matter). Service: 02/22/2018 by email. [500463] [Caryn Borg-Breen] [Entered: 02/22/2018 04:30 PM] (1) |
| Feb 22, 2018 | 66 | Notice from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. regarding conflicts with oral argument (Counsel for Plaintiffs-Appellants has conflicts during April 30-May 4, 2018 due to trial in another matter). Service: 02/22/2018 by email. [500464] [Caryn Borg-Breen] [Entered: 02/22/2018 04:37 PM] (1) |
| Dec 26, 2017 | 64 | Notice from Cross-Appellant Actavis Laboratories UT, Inc. regarding conflicts with oral argument (January 8-10, February 12, and March 7-9, 2018). Service: 12/26/2017 by email. [485643] [John Rozendaal] [Entered: 12/26/2017 04:36 PM] (1) |
| Dec 22, 2017 | 62 | Notice from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. regarding conflicts with oral argument (Counsel for Plaintiffs-Appellants has conflicts during January 8-12, 2018, and March 7-9 and 12, 2018 due to scheduling commitments in other matters.). Service: 12/22/2017 by email. [485319] [Jessica Mackay] [Entered: 12/22/2017 03:02 PM] (1) |
| Dec 22, 2017 | 63 | 6 paper copies of the Confidential Joint Appendix in 5 Volumes [59] received from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [485353] [JCP] [Entered: 12/22/2017 03:39 PM] (0) |
| Dec 19, 2017 | 61 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 12/26/2017. [483803] [FMS] [Entered: 12/19/2017 02:14 PM] (0) |
| Dec 18, 2017 | 58 | Statement of Compliance with Fed. Cir. R. 33 for Appellants HZNP Limited, Horizon Pharma Ireland Limited, Horizon Pharma USA, Inc. and Cross-Appellant Actavis Laboratories UT, Inc.. Service: 12/18/2017 by email. [483525] [Jessica Mackay] [Entered: 12/18/2017 10:59 PM] (4) |
| Dec 11, 2017 | 55 | 6 paper copies of the Reply Brief [54] received from Cross-Appellant Actavis Laboratories UT, Inc. [481697] [JCP] [Entered: 12/11/2017 04:05 PM] (0) |
| Dec 11, 2017 | 56 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: CONFIDENTIAL JOINT APPENDIX Service: 12/11/2017 by email. [481837] [Robert Green] [Entered: 12/11/2017 11:52 PM] (0) |
| Dec 11, 2017 | 57 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: JOINT APPENDIX. Service: 12/11/2017 by email. [481838] [Robert Green] [Entered: 12/11/2017 11:56 PM] (2249) |
| Dec 11, 2017 | 59 | CONFIDENTIAL JOINT APPENDIX FILED for HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [56]. Number of Pages: 2278. Service: 12/11/2017 by email. The paper copies of the brief should be received by the court on or before 12/27/2017. [483749] [FMS] [Entered: 12/19/2017 12:41 PM] (0) |
| Dec 11, 2017 | 60 | APPENDIX FILED for HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [57]. Number of Pages: 2249. Service: 12/11/2017 by email. [483758] [FMS] [Entered: 12/19/2017 12:57 PM] (2249) |
| Dec 4, 2017 | 53 | TENDERED from Cross-Appellant Actavis Laboratories UT, Inc.. Title: REPLY BRIEF. Service: 12/04/2017 by email. [480082] [John Rozendaal] [Entered: 12/04/2017 05:07 PM] (23) |
| Dec 4, 2017 | 54 | REPLY BRIEF FILED for Cross-Appellant Actavis Laboratories UT, Inc. [53]. Number of Pages: 14. Service: 12/04/2017 by email. The paper copies of the brief should be received by the court on or before 12/15/2017. Appendix is due 12/11/2017. [481112] [FMS] [Entered: 12/08/2017 08:53 AM] (23) |
| Nov 29, 2017 | 52 | 6 paper copies of the Corrected Reply Brief [51] received from Appellants Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [478939] [CW] [Entered: 11/29/2017 02:13 PM] (0) |
| Nov 21, 2017 | 49 | Notice of Correction to the Brief Doc No. [48] for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 11/21/2017 by email. [477399] [Caryn Borg-Breen] [Entered: 11/21/2017 12:35 PM] (2) |
| Nov 21, 2017 | 50 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: CORRECTED RESPONSE BRIEF. Service: 11/21/2017 by email. [477402] [Caryn Borg-Breen] [Entered: 11/21/2017 12:37 PM] (80) |
| Nov 21, 2017 | 51 | REPLY BRIEF FILED for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [50]. Number of Pages: 66. Service: 11/20/2017 by email. The paper copies of the brief should be received by the court on or before 12/04/2017. Cross-Appellant's reply brief is due 12/04/2017. [478158] [FMS] [Entered: 11/27/2017 11:36 AM] (80) |
| Nov 20, 2017 | 48 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: RESPONSE BRIEF. Service: 11/20/2017 by email. [477155] [Caryn Borg-Breen] [Entered: 11/20/2017 04:59 PM] (0) |
| Nov 8, 2017 | 44 | Amended Entry of appearance for Caryn Borg-Breen as principal counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 11/08/2017 by email. [473986] [Robert Green] [Entered: 11/08/2017 11:09 AM] (2) |
| Nov 8, 2017 | 45 | Amended Entry of appearance for Jessica M. Tyrus as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 11/08/2017 by email. [473987] [Robert Green] [Entered: 11/08/2017 11:11 AM] (2) |
| Nov 8, 2017 | 46 | Amended Entry of appearance for Robert F. Green as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 11/08/2017 by email. [473989] [Robert Green] [Entered: 11/08/2017 11:12 AM] (2) |
| Nov 8, 2017 | 47 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [44], ERROR: The contact information on Attorney Caryn Borg-Breen's entry of appearance form does not match theinformation on counsel's ECF filer account. CORRECTION: ECF account information may be updated at www.pacer.gov, or counsel may file amended EOA form reflecting the correct contact information. [474024] [CAB] [Entered: 11/08/2017 12:55 PM] (0) |
| Oct 13, 2017 | 43 | 6 paper copies of the Opening Response Brief [42] received from Cross-Appellant Actavis Laboratories UT, Inc. [467597] [CW] [Entered: 10/13/2017 11:42 AM] (0) |
| Oct 10, 2017 | 40 | Amended Certificate of Interest for the Cross-Appellant Actavis Laboratories UT, Inc.. Service: 10/10/2017 by email. [466700] [John Rozendaal] [Entered: 10/10/2017 06:18 PM] (4) |
| Oct 10, 2017 | 41 | TENDERED from Cross-Appellant Actavis Laboratories UT, Inc.. Title: OPENING BRIEF. Service: 10/10/2017 by email. [466713] [John Rozendaal] [Entered: 10/10/2017 06:45 PM] (131) |
| Oct 10, 2017 | 42 | BRIEF FILED for Cross-Appellant Actavis Laboratories UT, Inc. [41]. Number of Pages: 74. Service: 10/10/2017 by email. The paper copies of the brief should be received by the court on or before 10/18/2017. Appellant's reply brief is due 11/20/2017. [467032] [FMS] [Entered: 10/11/2017 03:07 PM] (131) |
| Aug 31, 2017 | 39 | 6 paper copies of the Confidential Opening Brief [35] received from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [457979] [CW] [Entered: 08/31/2017 10:44 AM] (0) |
| Aug 29, 2017 | 38 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellant's principal brief [37] filed by Cross-Appellant Actavis Laboratories UT, Inc. Cross-Appellant Actavis Laboratories UT, Inc. brief is due 10/10/2017. Service as of this date by Clerk of Court**TEXT ONLY** ORDER [457493] [FMS] [Entered: 08/29/2017 03:56 PM] (0) |
| Aug 28, 2017 | 37 | MOTION of Cross-Appellant Actavis Laboratories UT, Inc. to extend the time to 10/10/2017 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 08/28/2017 by email. [457170] [Kristina Caggiano Kelly] [Entered: 08/28/2017 06:09 PM] (5) |
| Aug 24, 2017 | 34 | **TEXT ONLY** ORDER mooting motion to waive confidentiality requirements [29] filed by Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [456447] [FMS] [Entered: 08/24/2017 03:35 PM] (0) |
| Aug 16, 2017 | 31 | Notice of Correction to the Brief Doc No. [28], confidential Brief Doc No. [27] for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 08/16/2017 by email. [454564] [Caryn Borg-Breen] [Entered: 08/16/2017 04:46 PM] (3) |
| Aug 16, 2017 | 32 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: CORRECTED CONFIDENTIAL OPENING BRIEF Service: 08/16/2017 by email. [454568] [Caryn Borg-Breen] [Entered: 08/16/2017 04:50 PM] (0) |
| Aug 16, 2017 | 33 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: CORRECTED OPENING BRIEF. Service: 08/16/2017 by email. [454576] [Caryn Borg-Breen] [Entered: 08/16/2017 05:23 PM] (577) |
| Aug 16, 2017 | 35 | CONFIDENTIAL BRIEF FILED for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [32]. Number of Pages: 64. Service: 08/16/2017 by email. The paper copies of the brief should be received by the court on or before 09/01/2017. [456535] [FMS] [Entered: 08/25/2017 08:47 AM] (0) |
| Aug 16, 2017 | 36 | BRIEF FILED for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. [33]. Number of Pages: 64. Service: 08/16/2017 by email. Cross-Appellant Actavis Laboratories UT, Inc. brief is due 09/25/2017. [456537] [FMS] [Entered: 08/25/2017 08:54 AM] (577) |
| Aug 15, 2017 | 30 | Note to the File: Official caption revised to reflect 1:14-cv-07992, 1:15-cv-05025, 1:15-cv-06131, 1:15-cv- 06989, 1:15-cv-07742, and 1:16-cv-00645 as originating cases. [453996] [FMS] [Entered: 08/15/2017 10:32 AM] (0) |
| Aug 14, 2017 | 27 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: CONFIDENTIAL OPENING BRIEF Service: 08/14/2017 by email. [453905] [Caryn Borg-Breen] [Entered: 08/14/2017 09:43 PM] (0) |
| Aug 14, 2017 | 28 | TENDERED from Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Title: OPENING BRIEF. Service: 08/14/2017 by email. [453906] [Caryn Borg-Breen] [Entered: 08/14/2017 09:46 PM] (0) |
| Aug 14, 2017 | 29 | MOTION of Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. to waive confidentiality requirements. Any response is due within 10 days of service [Consent: not addressed]. Service: 08/14/2017 by email. [453907] [Caryn Borg-Breen] [Entered: 08/14/2017 09:54 PM] (37) |
| Aug 8, 2017 | 26 | Letter from Appellants HZNP Limited, Horizon Pharma Ireland Limited, Horizon Pharma USA, Inc. and Cross-Appellant Actavis Laboratories UT, Inc. requesting correction to official caption. Service: 08/08/2017 by email. [452328] [Jessica Mackay] [Entered: 08/08/2017 03:54 PM] (2) |
| Aug 2, 2017 | 25 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [450839] [JCA] [Entered: 08/02/2017 10:00 AM] (0) |
| Jul 19, 2017 | 24 | ORDER granting motion to consolidate appeals [23] filed by Cross-Appellant Actavis Laboratories UT, Inc. and Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited in 17-2149; Appellants’ opening brief is due no later than August 14, 2017. All remaining deadlines are to be calculated in accordance with Federal Circuit Rule 31(a). Service: 07/19/2017 by clerk. [447715] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [NL] [Entered: 07/19/2017 03:40 PM] (2) |
| Jul 14, 2017 | 23 | MOTION of Appellants HZNP Limited, Horizon Pharma Ireland Limited, Horizon Pharma USA, Inc. and Cross-Appellant Actavis Laboratories UT, Inc. to consolidate appeals (17-2149/17-2202, 17-2152/17-2206, and 17-2153/17-2203). Any response is due within 10 days of service [Consent: unopposed]. Service: 07/14/2017 by email. [446747] [John Rozendaal] [Entered: 07/14/2017 06:31 PM] (7) |
| Jun 30, 2017 | 22 | Amended Certificate of Interest for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443440] [Caryn Borg-Breen] [Entered: 06/30/2017 12:17 PM] (4) |
| Jun 29, 2017 | 18 | Corrected Entry of appearance for Caryn C. Borg-Breen as principal counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/29/2017 by email. [443255] [Caryn Borg-Breen] [Entered: 06/29/2017 04:29 PM] (2) |
| Jun 29, 2017 | 19 | Corrected Entry of appearance for Robert F. Green as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/29/2017 by email. [443257] [Caryn Borg-Breen] [Entered: 06/29/2017 04:30 PM] (2) |
| Jun 29, 2017 | 20 | Corrected Entry of appearance for Jessica M. Tyrus as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/29/2017 by email. [443258] [Caryn Borg-Breen] [Entered: 06/29/2017 04:32 PM] (2) |
| Jun 29, 2017 | 21 | Corrected Certificate of Interest for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/29/2017 by email. [443259] [Caryn Borg-Breen] [Entered: 06/29/2017 04:33 PM] (4) |
| Jun 28, 2017 | 16 | Notice of Rejection to Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc., the following document(s) cannot be filed: attorney entries of appearance ([4], [5], [6]) and certificate of interest [7]. Reasons: missing information. See order for additional details. [442775] [CMP] [Entered: 06/28/2017 11:59 AM] (1) |
| Jun 28, 2017 | 17 | NOTICE OF DEFICIENCY: The docketing statement Document No. [8] filed by Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited in 17-2149 is incomplete for the explaination regarding mediation and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. [442815] [CMP] [Entered: 06/28/2017 12:45 PM] (0) |
| Jun 27, 2017 | 4 | Entry of appearance for Caryn C. Borg-Breen as principal counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442525] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:38 PM] (0) |
| Jun 27, 2017 | 5 | Entry of appearance for Robert F. Green as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442526] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:40 PM] (0) |
| Jun 27, 2017 | 6 | Entry of appearance for Jessica M. Tyrus as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442527] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:41 PM] (0) |
| Jun 27, 2017 | 7 | Certificate of Interest for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442531] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:42 PM] (0) |
| Jun 27, 2017 | 8 | Docketing Statement for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442532] [Robert Green] [Entered: 06/27/2017 04:43 PM] (0) |
| Jun 27, 2017 | 9 | Transcript Purchase Order Form for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. indicating that a transcript is already on file. Service: 06/27/2017 by email. [442533] [Robert Green] [Entered: 06/27/2017 04:44 PM] (2) |
| Jun 27, 2017 | 10 | Entry of appearance for John Christopher Rozendaal as principal counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442556] [John Rozendaal] [Entered: 06/27/2017 05:19 PM] (2) |
| Jun 27, 2017 | 11 | Certificate of Interest for the Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442557] [John Rozendaal] [Entered: 06/27/2017 05:20 PM] (3) |
| Jun 27, 2017 | 12 | Docketing Statement for the Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442558] [John Rozendaal] [Entered: 06/27/2017 05:21 PM] (4) |
| Jun 27, 2017 | 13 | Entry of appearance for Michael E. Joffre as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442566] [Michael Joffre] [Entered: 06/27/2017 05:30 PM] (2) |
| Jun 27, 2017 | 14 | Entry of appearance for Kristina Caggiano Kelly as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442570] [Kristina Caggiano Kelly] [Entered: 06/27/2017 05:35 PM] (2) |
| Jun 27, 2017 | 15 | Entry of appearance for William H. Milliken as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442573] [William Milliken] [Entered: 06/27/2017 05:39 PM] (2) |
| Jun 22, 2017 | 2 | Note to file: The following cases are associated:17-2149 Lead with 17-2202 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [441303] [17-2149, 17-2202] [FMS] [Entered: 06/22/2017 10:36 AM] (0) |
| Jun 22, 2017 | 3 | Note to file: 17-2152 (COMPANION started 06/22/2017) with 17-2149 and 17-2153 (COMP COMPANION started 06/22/2017) with 17-2149. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [441445] [17-2149, 17-2152, 17-2153] [FMS] [Entered: 06/22/2017 03:00 PM] (0) |
| Jun 13, 2017 | 1 | Appeal docketed. Received: 06/12/2017. [438956]Entry of Appearance due 06/27/2017. Certificate of Interest is due on 06/27/2017. Docketing Statement due 06/27/2017. Appellant/Petitioner's brief is due 08/14/2017. [FMS] [Entered: 06/13/2017 04:16 PM] (21) |
